Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Appoints Merdad Parsey, MD, PhD as Chief Medical Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2019 | 08:32am EST

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.

Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.

“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”

Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/12GILEAD SCIENCES : Report
CO
11/11GILEAD SCIENCES : New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Dur..
AQ
11/11GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
AQ
11/11GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
AQ
11/11GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
AQ
11/08GILEAD SCIENCES : Did You Invest in Gilead Sciences?
BU
11/08GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
BU
11/08GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
BU
11/08GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
BU
11/07GILEAD SCIENCES : United States sues Gilead for patent violation on HIV preventi..
AQ
More news
Financials (USD)
Sales 2019 22 290 M
EBIT 2019 11 488 M
Net income 2019 4 319 M
Finance 2019 2 986 M
Yield 2019 3,94%
P/E ratio 2019 17,8x
P/E ratio 2020 11,4x
EV / Sales2019 3,49x
EV / Sales2020 3,38x
Capitalization 80 729 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,00  $
Last Close Price 63,81  $
Spread / Highest target 48,9%
Spread / Average Target 22,2%
Spread / Lowest Target -5,97%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.01%80 729
VERTEX PHARMACEUTICALS23.71%52 716
REGENERON PHARMACEUTICALS-9.40%36 994
WUXI APPTEC CO., LTD.83.91%22 688
GENMAB39.63%14 293
BEIGENE, LTD.40.03%11 907